SCHEMBL15320045

SCHEMBL15320045

CCOC(=O)c1ccc(NC2CCCCCCC2)c([N+](=O)[O-])c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 3/20 0.68
ALOX15 P16050 2/20 0.68
KMT2A Q03164 4/20 0.64
ALDH1A1 P00352 5/20 0.63
MAPT P10636 5/20 0.63
RAB9A P51151 2/20 0.63
NPC1 O15118 1/20 0.63
PKM P14618 1/20 0.63
CRHBP P24387 1/20 0.63
CRHR2 Q13324 1/20 0.63
LMNA P02545 4/20 0.61
POLB P06746 3/20 0.61
KDM4E B2RXH2 1/20 0.61
PTGER4 P35408 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.55
MEN1 O00255 2/20 0.51
THRB P10828 2/20 0.51
PPARG P37231 2/20 0.51
GPR55 Q9Y2T6 1/20 0.51
VDR P11473 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2027705 1.00 HCAR3 (0.68) HCAR3ALOX15KMT2AALDH1A1MAPT
SCHEMBL15319505 1.00 HCAR3 (0.68) HCAR3ALOX15KMT2AALDH1A1MAPT
SCHEMBL15320956 1.00 HCAR3 (0.68) HCAR3ALOX15KMT2AALDH1A1MAPT
SCHEMBL15319810 0.99 HCAR3 (0.70) HCAR3ALOX15KMT2AALDH1A1MAPT
SCHEMBL15320365 0.97 HCAR3 (0.70) HCAR3ALOX15KMT2AALDH1A1MAPT
SCHEMBL15321361 0.94 HCAR3 (0.68) HCAR3ALOX15KMT2AALDH1A1MAPT
SCHEMBL7842728 0.94 ALOX15 (0.80) HCAR3ALOX15KMT2AALDH1A1MAPT
SCHEMBL7843052 0.94 KMT2A (0.64) HCAR3ALOX15KMT2AALDH1A1MAPT
SCHEMBL4124929 0.91 ALOX15 (0.65) HCAR3ALOX15KMT2AALDH1A1MAPT
SCHEMBL4130039 0.90 KMT2A (0.63) HCAR3ALOX15KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597381-B2 Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2020-03-24 US disclosed
US-20190135782-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2019-05-09 US disclosed
US-10233171-B2 Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2019-03-19 US disclosed
US-20170233370-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2017-08-17 US disclosed
US-9580398-B2 Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2017-02-28 US disclosed
US-20150079035-A1 Compounds, Compositions, and Methods For Modulating Ferroptosis and Treating Excitotoxic Disorders NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-03-19 US disclosed
WO-2013152039-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2013-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10597381-B2 Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders AIFM2, GPX1, GPX4 HCAR3 783/4885ALOX15 93/4885KMT2A 2204/4885
US-20150079035-A1 Compounds, Compositions, and Methods For Modulating Ferroptosis and Treating Excitotoxic Disorders AIFM2, GPX1, GPX4 HCAR3 904/4885ALOX15 86/4885KMT2A 2411/4885
US-20170233370-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS AIFM2, GPX1, GPX4 HCAR3 783/4885ALOX15 93/4885KMT2A 2204/4885
US-10233171-B2 Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders AIFM2, GPX1, GPX4 HCAR3 783/4885ALOX15 93/4885KMT2A 2204/4885
US-20190135782-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS AIFM2, GPX1, GPX4 HCAR3 783/4885ALOX15 93/4885KMT2A 2204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.